MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., an RNAi oligonucleotide such as an siRNA, useful for targeting DUX4) covalently linked to an antibody (e.g., anti-TfR1 antibody).
1 - 30 . (canceled)
31 . A complex comprising a structure of formula (I): [R 1 ] n1 —R 2 , wherein each R 1 comprises a group of the formula (Ic), in which the antisense strand and the sense strand form a double stranded oligonucleotide:
or a pharmaceutically acceptable salt thereof,
wherein R 2 comprises a Fab comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20;
wherein R 1 is covalently linked at attachment point A to R 2 ; wherein n1 is an integer representing the number of instances of R 1 , and wherein each instance of R 1 is covalently linked to a different amino acid residue of the Fab.
32 . The complex of claim 31 , wherein each of the different amino acid residue is a lysine.
33 . The complex of claim 31 , wherein the heavy chain of the Fab comprises an N-terminal pyroglutamate.
34 . A method of reducing DUX4 expression in a subject, the method comprising administering to the subject a composition comprising the complex of claim 31 .
35 . The method of claim 34 , wherein reducing DUX4 expression comprises reducing DUX4 protein and/or DUX4 mRNA levels.
36 . A method of treating facioscapulohumeral muscular dystrophy (FSHD) in a subject, the method comprising administering to the subject a composition comprising the complex of claim 31 .
37 . The method of claim 36 , wherein the subject has aberrant production of DUX4 protein.
38 . A complex comprising a structure of formula (I): [R 1 ] n1 —R 2 , wherein each R 1 comprises a group of the formula (Ia):
or a pharmaceutically acceptable salt thereof,
wherein R 3 comprises an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of SEQ ID NO: 22 and a structure (5′→3′) of VP-mU*fG*mCmCmAmGmAmAmUmUmUmCmAfCmGmGmAmAmGmAmA*mC*mA, and
a sense strand comprising a nucleobase sequence of SEQ ID NO: 21 and a structure (5′→3′) of mU*mU*mCmUfUmCmCmGfUfGfAmAmAfUmUmCmUmGfG*mC*mA, wherein: mA, mC, mG, and mU are 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; fA, fC, fG, and fU are 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; “*” between two nucleosides represents a phosphorothioate linkage; the absence of “*” between two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5′-(E)-Vinylphosphonate;
wherein R 2 comprises a Fab comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20;
wherein R 1 is covalently linked at attachment point A to R 2 ; wherein n1 is an integer representing the number of instances of R 1 , and wherein each instance of R 1 is covalently linked to a different amino acid residue of the Fab.
39 . The complex of claim 38 , wherein each of the different amino acid residue is a lysine.
40 . The complex of claim 38 , wherein the heavy chain of the Fab comprises an N-terminal pyroglutamate.
41 . A method of reducing DUX4 expression in a subject, the method comprising administering to the subject a composition comprising the complex of claim 38 .
42 . The method of claim 41 , wherein reducing DUX4 expression comprises reducing DUX4 protein and/or DUX4 mRNA levels.
43 . A method of treating facioscapulohumeral muscular dystrophy (FSHD) in a subject, the method comprising administering to the subject a composition comprising the complex of claim 38 .
44 . The method of claim 43 , wherein the subject has aberrant production of DUX4 protein.
45 . A complex comprising a structure of formula (I): [R 1 ] n1 —R 2 , wherein each R 1 comprises a group of the formula (Ib):
or a pharmaceutically acceptable salt thereof,
wherein: mA, mC, mG, and mU are 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; fA, fC, fG, and fU are 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; “*” between two nucleosides represents a phosphorothioate linkage; the absence of “*” between two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5′-(E)-Vinylphosphonate;
wherein R 2 comprises a Fab comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20;
wherein R 1 is covalently linked at attachment point A to R 2 ; wherein n1 is an integer representing the number of instances of R 1 , and wherein each instance of R 1 is covalently linked to a different amino acid residue of the Fab.
46 . The complex of claim 45 , wherein each of the different amino acid residue is a lysine.
47 . The complex of claim 45 , wherein the heavy chain of the Fab comprises an N-terminal pyroglutamate.
48 . A method of reducing DUX4 expression in a subject, the method comprising administering to the subject a composition comprising the complex of claim 45 .
49 . The method of claim 48 , wherein reducing DUX4 expression comprises reducing DUX4 protein and/or DUX4 mRNA levels.
50 . A method of treating facioscapulohumeral muscular dystrophy (FSHD) in a subject, the method comprising administering to the subject a composition comprising the complex of claim 45 .
51 . The method of claim 50 , wherein the subject has aberrant production of DUX4 protein.
52 . A complex comprising a structure of the formula (Id):
or a pharmaceutically acceptable salt thereof,
wherein: mA, mC, mG, and mU are 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively;
fA, fC, fG, and fU are 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; “*” between two nucleosides represents a phosphorothioate linkage; the absence of “*” between two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5′-(E)-Vinylphosphonate;
wherein R 2 comprises a Fab comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20;
wherein n1 is an integer representing the number of instances of the group enclosed by square brackets, and wherein each instance of the group enclosed by square brackets is covalently linked to a different amino acid residue of the Fab.
53 . The complex of claim 52 , wherein each of the different amino acid residue is a lysine.
54 . The complex of claim 52 , wherein the heavy chain of the Fab comprises an N-terminal pyroglutamate.
55 . A method of reducing DUX4 expression in a subject, the method comprising administering to the subject a composition comprising the complex of claim 52 .
56 . The method of claim 55 , wherein reducing DUX4 expression comprises reducing DUX4 protein and/or DUX4 mRNA levels.
57 . A method of treating facioscapulohumeral muscular dystrophy (FSHD) in a subject, the method comprising administering to the subject a composition comprising the complex of claim 52 .
58 . The method of claim 57 , wherein the subject has aberrant production of DUX4 protein.